Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
Date:10/3/2007

CALGARY, Oct. 3 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 15th annual BioPartnering Europe conference in London, U.K. on Tuesday, October 9 at 9 a.m. The conference will be held at the Queen Elizabeth II Conference Centre from October 7-9, 2007.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
2. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
3. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
4. Comparison of Growth Techniques and Media for the Purpose of Plasmid Isolation from E. coli Using the Eppendorf Perfectprep Plasmid Mini Kit
5. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
6. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
7. Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment
8. Measuring siRNA-mediated knockdown of IL-8 mRNA
9. Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation
10. Media-savvy workers: New front in the War for Talent
11. Sonic Foundry upgrades Mediasite for podcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... monetization of intellectual property, today announced that Chardan ... global investment bank specializing in micro, small, and ... Spherix. The report, authored by ... Chardan, was published on March 31, 2015. The ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Earlier this ... a vibrant life sciences industry association that represents research-based ... members. , Jonathan Parker, AJO’s Vice President of ... Dinner in February, an event that attracted over 750 ... Don Wright, a 73 year old cancer survivor shared ...
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
(Date:3/31/2015)... Eastern Kentucky University is ranked ... of criminal justice degree programs by Nonprofitcollegesonline.com. , ... ideas and high quality educational opportunities,” Editor Liz ... We are confident that students will find both ... the site’s first “Students before Profits” list, and ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Pharmaceuticals is,pleased to announce the introduction of ... on medically based aesthetics and,utilize the clinical ... of,science-based, result-oriented products., Vitivia(TM),s first product ... have long been recognized as important tools ...
... 27 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the establishment of ... Federale de Lausanne (EPFL), focusing on Signal ... million endowment, the objective,of the chair is ...
... combination vaccine against Ebola and Marburg viruses using ... infection in monkeys. Researchers from the U.S. ... report their results today (Feb. 26) at the ... in Baltimore, MD. , VLPs are one of ...
Cached Biology Technology:JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2Combination vaccine protects monkeys from ebola and Marburg viruses 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Loyola University Chicago Stritch School of ... the National Institutes of Health to study vitamin D ... evaluate the relation between low vitamin D levels and ... disease. Evidence from numerous previous studies is "inconclusive ...
... N.C. Researchers at the University of North Carolina at ... and paste together different viruses in an effort to create ... clinical trial, the investigators found no side effects from using ... muscle protein in patients with muscular dystrophy. "This trial ...
... Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, ... the growth of laboratory-engineered blood vessels after they have ... step toward ensuring that blood vessels, and possibly other ... taking hold and working as expected. Until now, there ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Yale researchers develop a way to monitor engineered blood vessels as they grow in patients 2
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
ELF® 97 Immunohistochemistry Kit...
Biology Products: